This program will showcase both drugs and devices under
development to treat the second leading cause of blindness globally.  You will
also gain valuable perspectives from clinical and industry leaders.

Glaucoma Thank you graphic (1)


1:00 – 1:05 PM

Welcome and Glaucoma Market Overview

Presented By:
Ehsan Sadri, MD, FACS, CEO & Founder of Visionary Eye Institute/General Partner, and Co-Founder of Visionary Ventures Fund

1:05 – 2:15 PM

Company Showcase

Aerie Pharmaceuticals | Tom Mitro - President & COO
Smartlens | Savas Komban - CEO & Co-Founder
Equinox | John Berdahl, MD - Founder & Chief Medical Officer
Galimedix Therapeutics | Alexander Gebauer, MD, PhD - Executive Chairman
iSTAR Medical | Michel Vanbrabrant, MBA - CEO
Sanoculis | Nir Israeli - CEO & Co-Founder
Leo Lens | Dan Myers - CEO
TearClear | Robert Dempsey - CEO
Bionode | Jane Fischer - President & CEO

2:15 – 2:40 PM

KOL Perspectives on Glaucoma Therapies and Development

Ike Ahmed, MD, Medical Director - Prism Eye Institute
Janet Serle, MD, Professor of Ophthalmology & Director of Glaucoma Clinical and Research Fellowships - Mount Sinai School of Medicine
Paul Singh, MD - Eye Centers of Racine & Kenosha

Moderated By:
Ehsan Sadri, MD, FACS, CEO & Founder of Visionary Eye Institute/General Partner, and Co-Founder of Visionary Ventures Fund

2:40 – 3:30 PM

Industry Insights on Glaucoma Market

Mark Hagler, SVP, Head of Ophthalmics, Oncology & LTC - Sun Pharma
Robert Kissling, VP, Medical Affairs - Bausch + Lomb
Peter Sallstig, Global Head Development Division, Senior Vice President & Corporate Officer - Santen
Jehan Tamboowalla, Head of New Ophthalmic Products - Novartis
Ramin Valian, VP, Marketing Interventional Glaucoma, Reimbursement Pipeline – Allergan

Moderated By:
Robert Rothman, MD, Partner at OCLI/Glaucoma Consultants of Long Island Founding Partner and Principal of InFocus Capital Partners

3:30 – 4:30 PM

Virtual Networking


Aerie Pharmaceuticals

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye. In the United States, Aerie markets Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor, and Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Aerie is expanding globally, with offices and clinical development activities in Europe and Japan. Rhokiinsa® (netarsudil ophthalmic solution) 0.02% has been approved in the EU and Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% has been filed with the EMA. Aerie is also pursuing additional product candidates in ophthalmology, including a Phase 2 dry eye program, AR-15512 (TRPM8 agonist), and two clinical-stage retina programs, AR-1105 (dexamethasone) Sustained Release Implant and AR-13503 (Rho kinase/Protein kinase C inhibitor) Sustained Release Implant, and exploring the development potential of other assets from its proprietary library of small-molecule multi-kinase inhibitors.


Allergan plc (NYSE: AGN), an AbbVie Inc (NYSE: ABBV) company, is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. Allergan markets leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics.


Sanoculis is developing and markets the MIMS (Minimally Invasive Micro Sclerostomy) device and technique for the treatment of the Glaucoma.
MIMS is simple, fast, and minimally invasive. During the procedure, a sclero-corneal drainage channel is created to reduce IOP. The novelty of the solution is that the channel ensures long-lasting controlled fluid flow with minor complications. MIMS consists of a disposable sterile tool and a multi-use external machine. Its expected benefits are: a stent-less procedure, low risk of complications, it is suitable for most Glaucoma patients, has the potential for medication reduction, can be easily combined with Cataract surgery and surgeon-friendly, automatic with short learning curve. MIMS is designed to reduce caring costs through procedure simplicity, low cost, fewer post-surgical complications and less hospitalization.



Learn how your company can get involved in another successful OIS meeting.


Gain valuable exposure and visibility for your company's branding.


Weekly Newsletters About The Latest In Ophthalmic Innovation.